Immunological control of β-amyloid levels in vivo

Details Immunological control of β-amyloid levels in vivo Immunological control of β-amyloid levels in vivo

2005-03-29

2005-03-29

Patterson, Jr., Charles L. (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Catalytic antibody

C530S387300

Reexamination Certificate

active

06872554

ABSTRACT:
Disclosed are bispecific antibodies comprising a first antibody binding specificity which confers the ability of the bispecific antibody to cross the blood-brain barrier, and a second antibody specificity conferring the ability of the bispecific antibody to bind to a β-amyloid epitope. Also disclosed are methods for inhibiting the formation of β-amyloid plaques in the brain of a human, of promoting the disaggregation of a preformed β-amyloid plaque. Such methods recite the administration of a bispecific antibody.

REFERENCES:
patent: 5439812 (1995-08-01), Benkovic et al.
patent: 6043069 (2000-03-01), Koentgen et al.
patent: 6140091 (2000-10-01), Raso et al.
patent: 6329508 (2001-12-01), Friden
patent: 6710226 (2004-03-01), Schenk
patent: 6743427 (2004-06-01), Schenk
patent: 6750324 (2004-06-01), Schenk et al.
patent: 20040081657 (2004-04-01), Schenk
patent: WO 9906066 (1999-02-01), None
patent: WO 9927944 (1999-06-01), None
patent: WO 0162801 (2001-08-01), None
Hardy, J.,Nature Genetics 1: 233-234 (1992).
Scheuner et al.,Nature Med. 2: 864-870 (1996).
Kowall et al.,Proc. Natl. Acad. Sci. USA 88: 7247-7251 (1991).
Gravina et al.,J. of Biol. Chem. 270: 7013-7016 (1995).
Bickel et al.,Proc. Natl. Acad. Sci. USA 90: 2618-2622 (1993).
Broadwell et al.,Exp Neurol. 142: 47-65 (1996).
Saito et al.,Proc. Natl. Acad. Sci. USA 92: 10227-10231 (1995).
Pardridge et al.,Pharmaceutical Res. 12: 807-816 (1995).
Descamps et al.,Am. J. Physiol. 270: H1149-H1158 (1996).
Duffy and Pardridge,Brain Res. 420: 32-38 (1987).
Dehouck et al.,J. Cell Biol. 138: 877-889 (1997).
Raso et al.,J. Biol. Chem. 272: 27623-27628 (1997).
Mallander and Voss,J. Biol. Chem. 269: 199-206 (1994).
Kang and Pardridge,J. Pharm. Exp. Ther. 269: 344-350 (1994).
Recht et al.,J. Neurosurg. 72: 941-945 (1990).
Solomon et al.,Proc. Natl. Acad. Sci. USA 94: 4109-4112 (1997).
Holtzman and DeMattos, U.S. Provisional Application No. 60/184,601 (Priority Document for WO 01/62801), “Method to Sequester Amyloid Beta Peptide in Human Therapy.”
Holtzman and DeMattos, U.S. Provisional Application No. 60/254,465 (Priority Document for WO 01/62801), “Method to Sequester Amyloid Beta Peptide in Human Therapy.”
Holtzman and DeMattos, U.S. Provisional Application No. 60/254,498 (Priority Document for WO 01/62801), “Method to Ameliorate Cognition Defects.”
Shin et al., Proc. Natl. Acad. Sci. USA 92:2820-2824 (1995).

Affiliated with

Also associated with

Rating

Immunological control of β-amyloid levels in vivo does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunological control of β-amyloid levels in vivo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunological control of β-amyloid levels in vivo will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3443264